Please ensure Javascript is enabled for purposes of website accessibility

Why Verastem Stock Jumped Briefly This Morning

By Evan Niu, CFA – Aug 10, 2020 at 4:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company reported second-quarter earnings and sold some drug development rights.

What happened

Shares of Verastem (VSTM 6.39%) jumped by as much as 11% this morning after the company reported second-quarter earnings and announced a deal to sell development rights to a drug. The stock gave up those gains and closed breakeven for the day.

So what

Revenue in the second quarter was $4.3 million, which resulted in an adjusted net loss of $20.5 million, or $0.12 per share. The developmental biotech company finished the quarter with $160.8 million in cash. Verastem also said it had entered into a definitive agreement to sell its global commercial and development rights to COPIKTRA (duvelisib) to Secura Bio in a deal worth up to $311 million. That transaction includes an up-front payment of $70 million, with additional possible payouts if Secura Bio can achieve various regulatory and sales milestones.

Scientist wearing lab coat and face mask holds up a vial, with a laptop on the table in front of her

Image source: Getty Images.

"The first half of 2020 has been a time of transformational change at Verastem Oncology," CEO Brian Stuglik said in a statement. "We recently announced our newest strategic transaction, the sale of COPIKTRA to Secura Bio, which allows us to monetize this asset while focusing our resources and efforts on advancing the VS-6766 and defactinib combination program in KRAS mutant solid tumors."

Now what

The deal with Secura Bio is expected to close during the third quarter and will provide Verastem with enough cash to fund its programs for VS-6766 and defactinib through 2024. Operating expenses in 2020 are expected to be in the range of $80 million to $90 million, or about 40% lower than in 2019. Starting in 2021, the company forecasts annual operating expenses of roughly $50 million.

Evan Niu, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Verastem Stock Quote
$0.44 (6.39%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.